Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP July 18, 2025…
CEDAR KNOLLS, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- With climate changes becoming more severe, veterinary sports medicine and rehabilitation…
Second-Quarter and First-Half 2025 ResultsConference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer,Mr PAUL DU SAILLANT, Deputy Chief…
Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS,…
Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal…
July 16, 2025 16:05 ET | Source: Glass House Brands Inc. LONG BEACH, Calif. and TORONTO, July 16, 2025 (GLOBE…
July 16, 2025 16:05 ET | Source: Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals,…
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15,…
SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC:…
July 15, 2025 16:36 ET | Source: Gain Therapeutics, Inc. BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics,…